Literature DB >> 14694155

Angiotensin II type 1-receptor mediated changes in heparan sulfate proteoglycans in human SV40 transformed podocytes.

Paul-Thomas Brinkkoetter1, Simone Holtgrefe, Fokko J van der Woude, Benito A Yard.   

Abstract

In patients with diabetic nephropathy, glomerular staining for heparan sulfate proteoglycans (HSPG) side chains and for agrin is decreased. In the present study, the influence of angiotensin II (AngII) on the production of HSPG in SV40 transformed podocytes was investigated. SV40 transformed human podocytes were cultivated with or without 1 microM AngII, and HSPG production was measured by sequential DEAE-anion exchange chromatography and HPLC-DEAE separation. Expression of agrin was studied by indirect immunofluorescence and Western blot analysis using specific mono- and polyclonal antibodies. DEAE separation of total glycosaminoglycans (GAG) revealed a significant increase of GAG in the culture supernatant and decrease in the cell and matrix layer when podocytes were cultured for 72 h in the presence of AngII. This was particularly found for HS-GAG. Qualitative analysis of HSPG, using gel filtration of HNO(2)-treated fractions, showed that AngII treatment decreased N-sulfation of HS-GAG side chains. Indirect immunofluorescence staining with anti-agrin polyclonal antibody was strongly decreased after AngII stimulation. A reduction in agrin expression in cell extracts could also be detected in Western blot analysis using an mAb. No changes in agrin mRNA were found after AngII stimulation. It is concluded from this study that AngII decreases the amount of HSPG on the cell surface and in the extracellular matrix of podocytes. Because HSPG play a fundamental role in the permselectivity of the glomerular basement membrane, these results thus may explain at least partially the antiproteinuric effects of angiotensin-converting enzyme inhibition in patients with diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14694155     DOI: 10.1097/01.asn.0000102476.50041.44

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  13 in total

Review 1.  Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise.

Authors:  Boutros El-Haddad; Scott Reule; Paul E Drawz
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

2.  Mechanisms of Metabolic Acidosis-Induced Kidney Injury in Chronic Kidney Disease.

Authors:  Donald E Wesson; Jerry M Buysse; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2020-01-27       Impact factor: 10.121

3.  ARB protects podocytes from HIV-1 nephropathy independently of podocyte AT1.

Authors:  Akihiro Shimizu; Jianyong Zhong; Yoichi Miyazaki; Tatsuo Hosoya; Iekuni Ichikawa; Taiji Matsusaka
Journal:  Nephrol Dial Transplant       Date:  2012-03-15       Impact factor: 5.992

4.  Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent.

Authors:  Taiji Matsusaka; Takako Asano; Fumio Niimura; Masaru Kinomura; Akihiro Shimizu; Ayumi Shintani; Ira Pastan; Agnes B Fogo; Iekuni Ichikawa
Journal:  Hypertension       Date:  2010-02-08       Impact factor: 10.190

Review 5.  Obesity in kidney disease: A heavyweight opponent.

Authors:  Raphael Jose Ferreira Felizardo; Marina Burgos da Silva; Cristhiane Favero Aguiar; Niels Olsen Saraiva Câmara
Journal:  World J Nephrol       Date:  2014-08-06

Review 6.  Gene expression in diabetic nephropathy.

Authors:  Daniela Hohenadel; Fokko J van der Woude
Journal:  Curr Diab Rep       Date:  2004-12       Impact factor: 4.810

7.  The potential role of complement alternative pathway activation in hypertensive renal damage.

Authors:  Chongjian Wang; Zhiyu Wang; Wen Zhang
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-27

Review 8.  Redox control of renal function and hypertension.

Authors:  Ravi Nistala; Adam Whaley-Connell; James R Sowers
Journal:  Antioxid Redox Signal       Date:  2008-12       Impact factor: 8.401

Review 9.  Losartan chemistry and its effects via AT1 mechanisms in the kidney.

Authors:  Feichao Xu; Caiping Mao; Yujuan Liu; Lei Wu; Zhice Xu; Lubo Zhang
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

10.  Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans.

Authors:  Arrigo F Cicero; Sibel Ertek
Journal:  Arch Med Sci       Date:  2010-09-07       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.